Tianjin Lisheng Pharmaceutical Co.,Ltd. (SHE:002393)
China · Delayed Price · Currency is CNY 22.10
-0.75 (-3.28%)
Mar 20, 2026, 1:35 PM CST
SHE:002393 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,393 | 1,332 | 1,145 | 1,141 | 1,087 |
Other Revenue | - | 4.01 | 7.7 | 6.05 | 4.67 |
| 1,393 | 1,336 | 1,153 | 1,147 | 1,092 | |
Revenue Growth (YoY) | 4.23% | 15.88% | 0.56% | 5.00% | -4.29% |
Cost of Revenue | - | 624.04 | 487.97 | 510.51 | 473.95 |
Gross Profit | 1,393 | 712.11 | 665.06 | 636.08 | 618 |
Selling, General & Admin | - | 494.08 | 424.61 | 448.45 | 466.29 |
Research & Development | - | 122.1 | 102.48 | 102.26 | 100.82 |
Other Operating Expenses | 922.71 | 20.19 | 19.64 | 24.1 | 22.33 |
Operating Expenses | 922.71 | 636.39 | 546.47 | 575.03 | 589.34 |
Operating Income | 469.96 | 75.72 | 118.6 | 61.05 | 28.66 |
Interest Expense | - | -2.66 | -0.75 | -0.88 | -0.32 |
Interest & Investment Income | - | 147.31 | 76.03 | 91.93 | 106.85 |
Currency Exchange Gain (Loss) | - | 0.01 | 0.01 | 0.11 | -0.06 |
Other Non Operating Income (Expenses) | -13.53 | -0.7 | 2.23 | -2.16 | -0.18 |
EBT Excluding Unusual Items | 456.43 | 219.69 | 196.12 | 150.05 | 134.95 |
Merger & Restructuring Charges | - | -6.31 | -4.99 | - | - |
Gain (Loss) on Sale of Investments | - | 2.9 | 0.62 | 0.28 | - |
Gain (Loss) on Sale of Assets | - | -0.1 | 238.7 | -34.82 | - |
Asset Writedown | - | -0.56 | -15.27 | -1.2 | -1.61 |
Other Unusual Items | - | 0.33 | 5.02 | 4.05 | 3.78 |
Pretax Income | 456.43 | 215.95 | 420.21 | 118.36 | 137.12 |
Income Tax Expense | 38.07 | 29.99 | 58.39 | 24.76 | 15.01 |
Earnings From Continuing Operations | 418.37 | 185.96 | 361.83 | 93.61 | 122.11 |
Minority Interest in Earnings | - | -1.43 | - | - | - |
Net Income | 418.37 | 184.53 | 361.83 | 93.61 | 122.11 |
Net Income to Common | 418.37 | 184.53 | 361.83 | 93.61 | 122.11 |
Net Income Growth | 126.72% | -49.00% | 286.54% | -23.34% | 1317.31% |
Shares Outstanding (Basic) | 258 | 256 | 258 | 257 | 255 |
Shares Outstanding (Diluted) | 258 | 256 | 258 | 257 | 255 |
Shares Change (YoY) | 0.77% | -0.83% | 0.58% | 0.71% | 5.72% |
EPS (Basic) | 1.62 | 0.72 | 1.40 | 0.36 | 0.48 |
EPS (Diluted) | 1.62 | 0.72 | 1.40 | 0.36 | 0.48 |
EPS Growth | 125.00% | -48.57% | 284.30% | -23.88% | 1240.62% |
Free Cash Flow | - | 34.51 | 138.29 | 290.47 | 108.1 |
Free Cash Flow Per Share | - | 0.14 | 0.54 | 1.13 | 0.42 |
Dividend Per Share | - | 0.350 | 0.429 | 0.214 | 0.214 |
Dividend Growth | - | -18.34% | 100.00% | - | 200.14% |
Gross Margin | 100.00% | 53.30% | 57.68% | 55.48% | 56.60% |
Operating Margin | 33.75% | 5.67% | 10.29% | 5.32% | 2.62% |
Profit Margin | 30.04% | 13.81% | 31.38% | 8.16% | 11.18% |
Free Cash Flow Margin | - | 2.58% | 11.99% | 25.33% | 9.90% |
EBITDA | 546.92 | 152.69 | 185.03 | 126.25 | 87.94 |
EBITDA Margin | 39.27% | 11.43% | 16.05% | 11.01% | 8.05% |
D&A For EBITDA | 76.96 | 76.96 | 66.43 | 65.2 | 59.28 |
EBIT | 469.96 | 75.72 | 118.6 | 61.05 | 28.66 |
EBIT Margin | 33.75% | 5.67% | 10.29% | 5.32% | 2.62% |
Effective Tax Rate | 8.34% | 13.89% | 13.89% | 20.92% | 10.95% |
Revenue as Reported | - | 1,336 | 1,153 | 1,147 | 1,092 |
Advertising Expenses | - | 266.99 | 253.43 | 264.36 | 283.37 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.